News

TECFIDERA is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERA is indicated as monotherapy for the treatment of RRMS to reduce the frequency of

BioInvent has successfully manufactured ADC-1013 (a FIND optimized n-CoDeR antibody) and will fulfill the remaining CMC activities required to supply drug product to the First-in-Human study, expected to

As part of the agreement, the firms have announced the launch of Pamorelin in Singapore for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer. Under the

FDA stated that currently there is no sufficient evidence to support approval of QRxPharma’s pain drug Moxduo. According to FDA, clinical information showing a clear benefit over oxycodone

As per the deal, Abiogen granted Lee’s Pharm an exclusive license and right for registering, importing, marketing, distributing and selling Attila in the territory, for the two orphan/rare

Nuwiq, the first new generation FVIII replacement protein derived from a human cell line, is produced without animal derived products, and devoid of non human epitopes thought to

The company develops new treatments for Alzheimer’s disease (AD) based on technology licensed from Massachusetts General Hospital. The trial is for the company’s lead program, ALZT-OP1, a new

The drug belongs to a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors that provides a new approach to treat diabetes by increasing the loss

With the approval, Vectibix becomes the first and only biologic to provide a significant survival benefit as a first-line treatment with FOLFOX for patients with wild-type KRAS mCRC.